Stem Cell Therapy advancements, page-299

Oh Mangoman,

They bought MSB shares at $2.30. I think they irrefutably made a mistake in their MSB investment, as did I in mine....

I was clearly talking about the potential synergies of Surgcenter with Orthocell as was obvious in my post. They are an ambulatory hospital (equivalent of day hospitals in Oz) network in the US specialising in Orthopedic outpatient treatments particularly. Obviously they have keen and understandable interest in MSB's CLBP (chronic lower back pain) treatment trials, but OCC literally would offer them far more immediacy in terms of revenue and across a broader spectrum of their business - ATI and CelGro augmentation in tendon surgery, ACI as an alternative/compliment to knee and hip replacements they commonly perform.

They could have bought the entire OCC business for the $110 million USD they invested in MSB and be already earning revenue from approved products in bone related procedures already.

I scratched my head at the time at their choice of MSB over OCC, but funnily enough never mind a private capital investment into any free cash flow negative stocks I own that are struggling for cash. I am wierd like that.